Tech Company Financing Transactions
Candel Therapeutics Funding Round
Candel Therapeutics, based in Needham, secured $100 million from RTW Investments.
Transaction Overview
Company Name
Announced On
2/19/2026
Transaction Type
Debt
Amount
$100,000,000
Round
Undisclosed
Investors
Proceeds Purpose
This non-dilutive strategic financing will support the U.S. launch of aglatimagene besadenovec, assuming FDA approval, and will allow us to further invest in what we believe will be a world class commercial program.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
117 Kendrick St. 450
Needham, MA 02494
USA
Needham, MA 02494
USA
Phone
Website
Email Address
Overview
Candel Therapeutics is a Massachusetts based biotechnology company developing our proprietary immuno-oncology platforms, including they are Gene Mediated Cytotoxic Immunotherapy (GMCI�) platform and our rQNestin34.5 platform for the treatment of solid tumors.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Estuardo Aguilar-Cordova
Chief Medical Officer
Laura Aguilar
VP - Bus. Development
Brian Guzik
VP - Bus. Development
Stephen Rocamboli
VP - Manufacturing
Daniel Giroux
VP - R & D
Andrea Manzanera
Browse more venture capital transactions:
Prev: 2/19/2026: Kombo venture capital transaction
Next: 2/19/2026: SIQ Basketball venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs